Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model

Trastuzumab (Herceptin) has improved therapy of breast cancer. Only patients overexpressing ERBB2 are treated with trastuzumab, whereas its use in tumours without ERBB2 expression is useless. This led to the concept that the subgroup of trastuzumab-sensitive tumours is ‘ERBB2-dependent’, meaning tha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hermes, M, Schormann, W, Brulport, M, Uhlemann, K, Lupatsch, F, Horn, L C, Schumann, A, Allgaier, C, Weishaupt, M, Engeland, K, Müller, G A, Mössner, J, Bauer, A, Schiffer, I B, Gebhard, S, Schmidt, M, Lausch, E, Prawitt, D, Wilhelm, C, Hengstler, J G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2008
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2391101/
https://ncbi.nlm.nih.gov/pubmed/18454161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604318
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados